At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Anastrozole +1 moredrug
Likely dose
Anastrozole 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo-controlled Phase II Study of Anastrozole in Patients With Pulmonary Arterial Hypertension
In Brief
A Phase 2 clinical trial evaluating Anastrozole and Placebo for Pulmonary Arterial Hypertension. Completed, enrolled 18 participants across 3 sites.
Detailed Summary
The main purpose of this clinical trial is to study the safety and efficacy of anastrozole in adults diagnosed with pulmonary arterial hypertension (PAH). The study will evaluate how well the drug is tolerated. The study will also evaluate if anastrozole effects estradiol (E2) hormone levels, a sex hormone, and improves the function of the lower right chamber of the heart (right ventricle).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartOct 2012
Primary CompletionJun 2015
Study CompletionSep 2015
TodayJul 2026
First PostedMar 6, 2012
Enrollment StartOct 1, 2012
Primary CompletionJun 1, 2015
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 14.3 years ago
Interventions
Anastrozoledrug
1 mg tablet to be taken 1 time daily
Placebodrug
1 mg tablet to be taken 1 time daily